Seres Therapeutics' SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study
Seres Therapeutics NASDAQ: MCRB reported results from an investigator-sponsored study of SER-155 in immune checkpoint inhibitor-related enterocolitis, or irEC, saying the data support further evaluation of the live biotherapeutic as a potential non-immunosuppressive treatment option for cancer patients experiencing the gastrointestinal toxicity.
Seres Therapeutics: Speculative Gem Backed By SER‑155 FDA Breakthrough
Seres Therapeutics's VOWST divestiture injected cash, retired debt, and refocused the company as a clinical‑stage microbiome specialist. Their current lead candidate is SER‑155, which seems to reduce bloodstream infections up to 77% according to their Phase 1b trial. SER-155 also holds the FDA's Breakthrough and Fast Track designations. MCRB targets more interim Phase 2 SER‑155 data within 12 months.
